{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:01:35Z","timestamp":1792612895457,"version":"4.5.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Chimeric antigen receptor (CAR) T cells have been successfully used in the therapy of B cell leukemia and lymphoma, but still have many challenges in their use for treating T cell malignancies, such as the lack of unique tumor antigens, their limitation of T cell expansion, and the need for third party donors or genome editing. Therefore, we need to find novel targets for CAR T cell therapy to overcome these challenges. Here, we found that both adult T-cell leukemia\/lymphoma (ATLL) patients and ATLL cells had increased CCR8 expression but did not express CD7. Moreover, targeting CCR8 in T cells did not impair T cell expansion <jats:italic>in vitro<\/jats:italic>. Importantly, anti-CCR8 CAR T cells exhibited antitumor effects on ATLL- and other CCR8-expressing T-ALL cells <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic>, and prolonged the survival of ATLL and Jurkat tumor-bearing mouse models. In conclusion, these collective results show that anti-CCR8 CAR T cells possess strong antitumor activity and represent a promising therapeutic approach for ATLL and CCR8<jats:sup>+<\/jats:sup> tumors.<\/jats:p>","DOI":"10.3389\/fimmu.2022.808347","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T09:03:31Z","timestamp":1653555811000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["The Chemokine Receptor CCR8 Is a Target of Chimeric Antigen T Cells for Treating T Cell Malignancies"],"prefix":"10.3389","volume":"13","author":[{"given":"Diwei","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xindong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruocong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxuan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youguo","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suna","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangqiu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongsheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qifa","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pentao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinwen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LiHua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-Term Safety and Activity of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1): A Single-Arm, Multicentre, Phase 1-2 Trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults With B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-Edited T Cells Expressing a CD7-Specific CAR for the Therapy of T-Cell Malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1271","article-title":"Eradication of T-ALL Cells by CD7-Targeted Universal CAR-T Cells and Initial Test of Ruxolitinib-Based CRS Management","volume":"27","author":"Li","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00389","article-title":"Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-In-Human, Phase I Trial","volume":"39","author":"Pan","year":"2021","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/10245330512331390393","article-title":"Treatment of T-Cell Lymphoma","author":"Hotta","year":"2005","journal-title":"Hematology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V50.3.481.481","article-title":"Adult T-Cell Leukemia: Clinical and Hematologic Features of 16 Cases","volume":"50","author":"Uchiyama","year":"1977","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70202-5","article-title":"Human T-Cell Leukaemia Virus Type I and Adult T-Cell Leukaemia-Lymphoma","volume":"15","author":"Ishitsuka","year":"2014","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","article-title":"Diagnostic Criteria and Classification of Clinical Subtypes of Adult T-Cell Leukaemia-Lymphoma. A Report From the Lymphoma Study Group (1984-87)","volume":"79","author":"Shimoyama","year":"1991","journal-title":"Br J Haematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12617","article-title":"Recent Advances in the Treatment of Adult T-Cell Leukemia-Lymphomas","volume":"106","author":"Choi","year":"2015","journal-title":"Cancer Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V58.3.645.645","article-title":"Surface Phenotype of Japanese Adult T-Cell Leukemia Cells Characterized by Monoclonal Antibodies","volume":"58","author":"Hattori","year":"1981","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10480","article-title":"Adult T-Cell Leukemia\/Lymphoma: A Cytopathologic, Immunocytochemical, and Flow Cytometric Study","volume":"96","author":"Dahmoush","year":"2002","journal-title":"Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.28.17251","article-title":"Identification of CCR8, the Receptor for the Human CC Chemokine I-309","volume":"272","author":"Roos","year":"1997","journal-title":"J Biol Chem"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1084\/jem.186.1.165","article-title":"Identification of CCR8: A Human Monocyte and Thymus Receptor for the CC Chemokine I-309","volume":"186","author":"Tiffany","year":"1997","journal-title":"J Exp Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.10.032","article-title":"Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer","volume":"45","author":"Plitas","year":"2016","journal-title":"Immunity"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1621280114","article-title":"CCR8(+)FOXp3(+) Treg Cells as Master Drivers of Immune Regulation","volume":"114","author":"Barsheshet","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-3585","article-title":"Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models","volume":"81","author":"Campbell","year":"2021","journal-title":"Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.4.1150","article-title":"Autocrine Antiapoptotic Stimulation of Cultured Adult T-Cell Leukemia Cells by Overexpression of the Chemokine I-309","volume":"98","author":"Ruckes","year":"2001","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00629","article-title":"A Novel Ten-Gene Signature Predicting Prognosis in Hepatocellular Carcinoma","volume":"8","author":"Zhou","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.249","article-title":"Toll-Like Receptor 2 Costimulation Potentiates the Antitumor Efficacy of CAR T Cells","volume":"32","author":"Lai","year":"2018","journal-title":"Leukemia"},{"key":"B21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13045-018-0572-x","article-title":"A Novel Generation 1928zt2 CAR T Cells Induce Remission in Extramedullary Relapse of Acute Lymphoblastic Leukemia","volume":"11","author":"Weng","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13045-015-0156-y","article-title":"Quantitative Evaluation of the Immunodeficiency of a Mouse Strain by Tumor Engraftments","volume":"8","author":"Ye","year":"2015","journal-title":"J Hematol Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12943-014-0285-x","article-title":"Genome-Wide Analyses Identify KLF4 as an Important Negative Regulator in T-Cell Acute Lymphoblastic Leukemia Through Directly Inhibiting T-Cell Associated Genes","volume":"14","author":"Li","year":"2015","journal-title":"Mol Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-662593","article-title":"Polycomb-Dependent Epigenetic Landscape in Adult T-Cell Leukemia","volume":"127","author":"Fujikawa","year":"2016","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-629527","article-title":"A T-Cell-Directed Chimeric Antigen Receptor for the Selective Treatment of T-Cell Malignancies","volume":"126","author":"Mamonkin","year":"2015","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2008.08.007","article-title":"Relationship Between CD107a Expression and Cytotoxic Activity","volume":"254","author":"Aktas","year":"2009","journal-title":"Cell Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13045-020-00856-8","article-title":"Bispecific CAR-T Cells Targeting Both CD19 and CD22 for Therapy of Adults With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia","volume":"13","author":"Dai","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133977","article-title":"TGF-Beta Inhibition via CRISPR Promotes the Long-Term Efficacy of CAR T Cells Against Solid Tumors","volume":"5","author":"Tang","year":"2020","journal-title":"JCI Insight"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.808347\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T09:03:35Z","timestamp":1653555815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.808347\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,26]]},"references-count":28,"alternative-id":["10.3389\/fimmu.2022.808347"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.808347","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,26]]},"article-number":"808347"}}